Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MLLT1 | Q03111 | 10/20 | 0.46 |
| ▸ | NLRP3 | Q96P20 | 4/20 | 0.43 |
| ▸ | MAOB | P27338 | 1/20 | 0.42 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.41 |
| ▸ | MLLT3 | P42568 | 4/20 | 0.40 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.39 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.36 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.36 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.36 |
| ▸ | YEATS2 | Q9ULM3 | 1/20 | 0.36 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23432690 | 0.81 | MLLT1 (0.49) | MLLT1NLRP3MAOBDNMT1MLLT3 | |
| SCHEMBL25124548 | 0.76 | CYP2C9 (0.37) | MLLT1NLRP3 | |
| SCHEMBL24783499 | 0.75 | MLLT1 (0.45) | MLLT1NLRP3MAOBDNMT1MLLT3 | |
| SCHEMBL6813380 | 0.74 | MLLT1 (0.58) | MLLT1DNMT1MLLT3SCN5AYEATS2 | |
| SCHEMBL24011032 | 0.72 | MLLT1 (0.56) | MLLT1NLRP3MAOBMLLT3 | |
| SCHEMBL13996528 | 0.71 | KEAP1 (0.50) | MAOB | |
| SCHEMBL2736776 | 0.71 | DNMT1 (0.46) | MLLT1MAOBDNMT1MLLT3SCN5A | |
| SCHEMBL18210819 | 0.70 | MLLT1 (0.51) | MLLT1DNMT1MLLT3YEATS2 | |
| SCHEMBL216157 | 0.70 | MLLT1 (0.57) | MLLT1NLRP3MAOBDNMT1MLLT3 | |
| SCHEMBL20689916 | 0.69 | DNMT1 (0.42) | MLLT1MAOBDNMT1MLLT3SCN5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230109839-A1 | THERAPEUTIC AGENT FOR TAUOPATHIES | Sumitomo Pharma Co., Ltd. (JP) | 2023-04-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230109839-A1 | THERAPEUTIC AGENT FOR TAUOPATHIES | MAPT, PSEN1, PSEN2 | MLLT1 1186/4885NLRP3 731/4885MAOB 2024/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.